Outlook Therapeutics (OTLK) Return on Invested Capital (2016 - 2025)
Outlook Therapeutics (OTLK) reported Return on Invested Capital of 0.02% for Q3 2025, up 1.0% year-over-year from 0.02% in Q3 2024, and down 8.69% quarter-over-quarter from 0.02% in Q2 2025.
Outlook Therapeutics (OTLK) Return on Invested Capital (2016 - 2025) Analysis & Trends
Outlook Therapeutics (OTLK) has 10 years of Return on Invested Capital data on file, last reported at 0.02% in Q3 2025.
- Return on Invested Capital for Q3 2025 came in at 0.02%, up 1.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 0.02% (up 1.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
- Return on Invested Capital slipped to 0.02% in Q3 2025 per OTLK's latest filing, from 0.02% in the prior quarter.
- Over five years, Return on Invested Capital peaked at 0.05% in Q3 2023 and troughed at 0.22% in Q2 2023.
- A 5-year average of 0.03% and a median of 0.01% in 2022 frame the typical range for Return on Invested Capital.
- The sharpest annual moves came in 2023 and 2024: Return on Invested Capital declined 20 bps in 2023, then advanced 22 bps in 2024.
- A 5-year view of Return on Invested Capital shows it stood at 0.06% in 2021, then increased by 27 bps to 0.04% in 2022, then jumped by 222 bps to 0.05% in 2023, then tumbled by 83 bps to 0.01% in 2024, then surged by 108 bps to 0.02% in 2025.
- Business Quant data shows OTLK's Return on Invested Capital at 0.02% in Q3 2025, 0.02% in Q2 2025, and 0.02% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.01% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -0.01% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -0.01% |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.02% |
| Jun 30, 2025 | 0.02% |
| Mar 31, 2025 | 0.02% |
| Sep 30, 2024 | 0.01% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 0.01% |
| Sep 30, 2023 | 0.05% |
| Jun 30, 2023 | -0.22% |
| Mar 31, 2023 | -0.04% |
| Sep 30, 2022 | -0.04% |
| Jun 30, 2022 | -0.02% |
| Mar 31, 2022 | -0.01% |
| Sep 30, 2021 | -0.06% |
| Jun 30, 2021 | -0.03% |
| Mar 31, 2021 | -0.08% |
| Sep 30, 2020 | -0.04% |
| Jun 30, 2020 | 0.06% |
| Sep 30, 2019 | 0.07% |
| Jun 30, 2019 | 0.03% |
| Sep 30, 2018 | 0.01% |